For any sponsors wondering whether the Office of New Drugs (OND) reorganization would adversely impact their development programs with changes to division leadership, OND director Peter Stein sought to assure them that they can proceed with business as usual.
A multitude of leadership positions are opening within OND due to the reorganization's establishment of more therapeutically-focused divisions.